Glonghui, Oct. 26 丨 Shanghai began booster vaccination of the inhaled COVID-19 vaccine today (26th). The vaccine is produced by Concinol-B (6185.HK), which means vaccination is officially open in the mainland. The inhaled vaccine is suitable for people aged 18 and above without underlying medical conditions, and was approved by the National Drug Administration for emergency use last month. Currently, inhaled vaccines are not currently used for basic immunization. Also, according to relevant national requirements, Shanghai residents currently only need to get 1 dose of same-source booster immunization or sequential booster immunization.

According to the UBS Research Report, the inhaled COVID-19 vaccine is expected to become mainstream in the future. Because it directly produces antibodies in the upper respiratory tract, it is expected to gradually replace injectable vaccines because there are fewer side effects and the management process is simpler. Allowing people to get the inhaled COVID-19 vaccine this time means that the mainland may restart large-scale vaccination campaigns in the short term to prepare for the gradual normalization of COVID-19 after the future. UBS reiterated its “buy” rating for Cansino, with a target price of HK$88. The stock is now at HK$64,65, with a total market value of HK$16 billion.